Christopher J M Williams
Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
Williams, Christopher J M; Elliott, Faye; Sapanara, Nancy; Aghaei, Faranak; Zhang, Liping; Muranyi, Andrea; Yan, Dongyao; Bai, Isaac; Zhao, Zuo; Shires, Michael; Wood, Henry M; Richman, Susan D; Hemmings, Gemma; Hale, Michael; Bottomley, Daniel; Galvin, Leanne; Cartlidge, Caroline; Dance, Sarah; Bacon, Chris M; Mansfield, Laura; Young-Zvandasara, Kathe; Sudan, Ajay; Lambert, Katy; Bibby, Irena; Coupland, Sarah E; Montazeri, Amir; Kipling, Natalie; Hughes, Kathryn; Cross, Simon S; Dewdney, Alice; Pheasey, Leanne; Leng, Cathryn; Gochera, Tatenda; Mangham, D Chas; Saunders, Mark; Pritchard, Martin; Stott, Helen; Mukherjee, Abhik; Ilyas, Mohammad; Silverman, Rafael; Hyland, Georgina; Sculthorpe, Declan; Thornton, Kirsty; Gould, Imogen; O'Callaghan, Ann; Brown, Nicholas; Turnbull, Samantha; Shaw, Lisa; Seymour, Matthew T; West, Nicholas P; Seligmann, Jenny F; Singh, Shalini; Shanmugam, Kandavel; Quirke, Philip
Authors
Faye Elliott
Nancy Sapanara
Faranak Aghaei
Liping Zhang
Andrea Muranyi
Dongyao Yan
Isaac Bai
Zuo Zhao
Michael Shires
Henry M Wood
Susan D Richman
Gemma Hemmings
Michael Hale
Daniel Bottomley
Leanne Galvin
Caroline Cartlidge
Sarah Dance
Chris M Bacon
Laura Mansfield
Kathe Young-Zvandasara
Ajay Sudan
Katy Lambert
Irena Bibby
Sarah E Coupland
Amir Montazeri
Natalie Kipling
Kathryn Hughes
Simon S Cross
Alice Dewdney
Leanne Pheasey
Cathryn Leng
Tatenda Gochera
D Chas Mangham
Mark Saunders
Martin Pritchard
Helen Stott
Dr ABHIK MUKHERJEE ABHIK.MUKHERJEE1@NOTTINGHAM.AC.UK
Clinical Associate Professor
MOHAMMAD ILYAS mohammad.ilyas@nottingham.ac.uk
Professor of Pathology
Rafael Silverman
Georgina Hyland
Declan Sculthorpe
Kirsty Thornton
IMOGEN PARKER Imogen.Parker@nottingham.ac.uk
Clinical Trial Manager
Ann O'Callaghan
Nicholas Brown
Samantha Turnbull
Lisa Shaw
Matthew T Seymour
Nicholas P West
Jenny F Seligmann
Shalini Singh
Kandavel Shanmugam
Philip Quirke
Abstract
Purpose: High tumor production of the EGFR ligands, amphiregulin (AREG) and epiregulin (EREG), predicted benefit from anti-EGFR therapy for metastatic colorectal cancer (mCRC) in a retrospective analysis of clinical trial data. Here, AREG/EREG IHC was analyzed in a cohort of patients who received anti-EGFR therapy as part of routine care, including key clinical contexts not investigated in the previous analysis.
Experimental Design: Patients who received panitumumab or cetuximab + chemotherapy for treatment of RAS wild-type mCRC at eight UK cancer centers were eligible. Archival formalin-fixed paraffin-embedded tumor tissue was analyzed for AREG and EREG IHC in six regional laboratories using previously developed artificial intelligence technologies. Primary endpoints were progression-free survival (PFS) and overall survival (OS).
Results: A total of 494 of 541 patients (91.3%) had adequate tissue for analysis. A total of 45 were excluded after central extended RAS testing, leaving 449 patients in the primary analysis population. After adjustment for additional prognostic factors, high AREG/ EREG expression (n ¼ 360; 80.2%) was associated with significantly prolonged PFS [median: 8.5 vs. 4.4 months; HR, 0.73; 95% confidence interval (CI), 0.56–0.95; P ¼ 0.02] and OS [median: 16.4 vs. 8.9 months; HR, 0.66 95% CI, 0.50–0.86; P ¼ 0.002]. The significant OS benefit was maintained among patients with right primary tumor location (PTL), those receiving cetuximab or panitumumab, those with an oxaliplatin- or irinotecan-based chemotherapy backbone, and those with tumor tissue obtained by biopsy or surgical resection.
Conclusions: High tumor AREG/EREG expression was associated with superior survival outcomes from anti-EGFR therapy in mCRC, including in right PTL disease. AREG/EREG IHC assessment could aid therapeutic decisions in routine practice.
Citation
Williams, C. J. M., Elliott, F., Sapanara, N., Aghaei, F., Zhang, L., Muranyi, A., …Quirke, P. (2023). Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer. Clinical Cancer Research, 29(20), 4153-4165. https://doi.org/10.1158/1078-0432.CCR-23-0859
Journal Article Type | Article |
---|---|
Acceptance Date | Jun 22, 2023 |
Online Publication Date | Jun 26, 2023 |
Publication Date | Oct 15, 2023 |
Deposit Date | Oct 5, 2023 |
Publicly Available Date | Oct 5, 2023 |
Journal | Clinical Cancer Research |
Print ISSN | 1078-0432 |
Electronic ISSN | 1557-3265 |
Publisher | American Association for Cancer Research |
Peer Reviewed | Peer Reviewed |
Volume | 29 |
Issue | 20 |
Pages | 4153-4165 |
DOI | https://doi.org/10.1158/1078-0432.CCR-23-0859 |
Keywords | Cancer Research; Oncology |
Public URL | https://nottingham-repository.worktribe.com/output/22989964 |
Publisher URL | https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-23-0859/727784/Associations-between-AI-Assisted-Tumor |
Files
Ccr-23-0859
(2.3 Mb)
PDF
Licence
https://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
Nostrin as a marker related to low grade and better prognosis in breast cancer
(2016)
Presentation / Conference Contribution
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search